Insights & Analysis

Industry insights that are curated and delivered to inform your dealmaking strategies. We select the most relevant information, providing a consistent, convenient source for exclusive intelligence and analysis.

All News Activism M&A Podcasts Private Cos. Private Equity Restructuring Scoops & Exclusives SPACs

Page 19

M&A

Bouchard Looks Back at Chancery, Ahead at Paul Weiss

By David Marcus
|
Published: December 17th, 2021
In Part Two of our extended interview, former Delaware Chancellor Andre Bouchard discusses the expansion of the Court of Chancery, changes in the litigation the court is seeing and his practice at Paul Weiss.
Activism

Drinks With The Deal: Eduardo Gallardo of Gibson Dunn

By David Marcus
|
Published: December 16th, 2021
Eduardo Gallardo, co-chair of M&A and chair of the activist defense group at Gibson Dunn, discusses the universal proxy, the Williams case and more on this week's Drinks With The Deal podcast.
M&A

Neogen, 3M Food Safety to Combine

By Nikitha Sattiraju
|
Published: December 14th, 2021
St. Paul, Minn.-based 3M agrees to separate its food safety business and combine it with Neogen in a deal that values the combined company at $9.3 billion.
M&A

SPX Flow Agrees to Lone Star Take-Private

By Tom Terrarosa
|
Published: December 13th, 2021
Analysts favor guaranteed cash in a roughly $3.6 billion deal over the execution risk associated with continuing as a standalone company amid a recent supply chain crunch.
M&A

Drinks With The Deal: Squire Patton Boggs' James Barresi

By David Marcus
|
Published: November 18th, 2021
James Barresi, who heads the firm's financial services practice, explains how his time as an in-house lawyer at US Bancorp in the 1990s has shaped his approach to private practice and how he works with clients considering a deal.
M&A

Book Review: Consider the Cocktail

By David Marcus
|
Published: November 4th, 2021
The new 'Oxford Companion to Spirits & Cocktails' treats the beverages in all of their aspects from production to history to brand management.
M&A

Drinks With The Deal: Krishna Veeraraghavan of Paul Weiss

By David Marcus
|
Published: October 14th, 2021
M&A lawyer Krishna Veeraraghavan talked about healthcare dealmaking and the risks of excessive antitrust regulation of combinations between biotech and pharma companies in the Drinks With The Deal podcast.
M&A

OpEd: ESG in Due Diligence Is Not Just Another Box to Check

By Deal Contributors
|
Published: October 5th, 2021
With ESG now a day-to-day focus for management and directors across industries, companies would be well-served to undertake a thoughtful assessment of ESG risks when evaluating potential targets in M&A activities.
 Company
Solutions
Contact The Deal
Tel:
1-888-667-3325
International:
+1-212-224-3069
Email:
[email protected]
© 2025 The Deal.

Part of the Delinian Group. Terms of Use, Commercial Terms & Conditions, Privacy Policy, Accessibility, Modern Slavery Act